共 171 条
[1]
De Morais SM(1994)Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 594-598
[2]
Wilkinson GR(2008)Stereoselective disposition of proton pump inhibitors Clin Drug Investig 28 263-279
[3]
Blaisdell J(2001)Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole Clin Pharmacokinet 40 411-426
[4]
Meyer UA(2006)The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta- analysis Am J Gastroenterol 101 1467-1475
[5]
Nakamura K(2007)Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori Clin Pharmacol Ther 81 521-528
[6]
Goldstein JA(2001)Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin Clin Pharmacol Ther 69 158-168
[7]
Andersson T(2004)CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori Clin Pharmacol Ther 76 201-209
[8]
Weidolf L(2003)A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole Nat Rev Drug Discov 2 132-139
[9]
Andersson T(2010)A randomized controlled trial: Efficacy and safety of azathromycin, ofloxacin, bismutu and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection Helicobacter 15 154-159
[10]
Hassan-Alin M(2010)Drug-drug interaction profiles of proton pump inhibitors Clin Pharmacokinet 1 509-533